Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider William Benton Jones Purchases 20,000 Shares of Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) insider William Benton Jones bought 20,000 shares of the company’s stock in a transaction on Monday, May 6th. The stock was purchased at an average cost of $1.73 per share, with a total value of $34,600.00. Following the completion of the transaction, the insider now owns 153,773 shares in the company, valued at $266,027.29. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Corvus Pharmaceuticals Price Performance

Shares of CRVS opened at $1.68 on Wednesday. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.05 and a 1-year high of $4.19. The stock has a market cap of $82.39 million, a PE ratio of -2.95 and a beta of 1.05. The firm has a fifty day moving average price of $1.78 and a 200 day moving average price of $1.78.

Corvus Pharmaceuticals (NASDAQ:CRVS) last released its quarterly earnings results on Tuesday, March 19th. The company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). As a group, equities analysts expect that Corvus Pharmaceuticals, Inc. will post -0.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CRVS. Cantor Fitzgerald restated an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Monday, April 1st. Oppenheimer lifted their price objective on shares of Corvus Pharmaceuticals from $7.00 to $8.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Mizuho reissued a “neutral” rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a report on Wednesday, March 27th.

Institutional Trading of Corvus Pharmaceuticals

A hedge fund recently raised its stake in Corvus Pharmaceuticals stock. Towerview LLC grew its stake in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 27.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 436,873 shares of the company’s stock after acquiring an additional 94,395 shares during the period. Corvus Pharmaceuticals comprises about 0.5% of Towerview LLC’s holdings, making the stock its 17th biggest position. Towerview LLC owned about 0.89% of Corvus Pharmaceuticals worth $769,000 at the end of the most recent reporting period. Institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.